Next Article in Journal
The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function
Next Article in Special Issue
Botulinum Toxin Induced Atrophy: An Uncharted Territory
Previous Article in Journal
Removal of Zearalenone and Zearalenols from Aqueous Solutions Using Insoluble Beta-Cyclodextrin Bead Polymer
Previous Article in Special Issue
Botulinum Toxin Type A Injection for Cervical Dystonia in Adults with Dyskinetic Cerebral Palsy
Article Menu
Issue 6 (June) cover image

Export Article

Open AccessArticle
Toxins 2018, 10(6), 217; https://doi.org/10.3390/toxins10060217

Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience

1
Department of Neurology, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain
2
Department of Neurodegenerative Diseases, UCL Institute of Neurology, London WC1N 3RX, UK
*
Author to whom correspondence should be addressed.
Received: 10 May 2018 / Revised: 25 May 2018 / Accepted: 25 May 2018 / Published: 28 May 2018
(This article belongs to the Special Issue Botulinum Toxin Treatment of Movement Disorders)
Full-Text   |   PDF [876 KB, uploaded 28 May 2018]   |  

Abstract

Botulinum toxin type A is one of the most useful treatments of sialorrhea in neurological disorders. Evidence for the use of incobotulinumtoxin A (inco-A) in the treatment of sialorrhea is limited. Thirty-six patients with sialorrhea were treated with infiltrations of inco-A into both parotid glands. The severity of sialorrhea was evaluated by the Drooling Severity Scale (DSS), and the Drooling Frequency Scale (DFS). Patients’ perceptions of clinical benefit were recorded via the Patient Global Impression of Improvement (PGI-I) scale. Following treatment, there was a significant difference in both the DFS and the DSS (p < 0.001). Clinical benefits on the basis of the PGI-I were present in up to 90% of patients. View Full-Text
Keywords: sialorrhea; neurological disorders; Parkinson’s disease; botulinum toxin type A; incobotulinumtoxin A sialorrhea; neurological disorders; Parkinson’s disease; botulinum toxin type A; incobotulinumtoxin A
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Martínez-Poles, J.; Nedkova-Hristova, V.; Escribano-Paredes, J.B.; García-Madrona, S.; Natera-Villalba, E.; Estévez-Fraga, C.; López-Sendón Moreno, J.L.; Avilés-Olmos, I.; Sánchez Díaz, G.; Martínez Castrillo, J.C.; Alonso-Canovas, A. Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience. Toxins 2018, 10, 217.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top